Rituximab therapy for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis
Postgraduate Medical Journal · 2025
DOI: 10.1093/postmj/qgaf034 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Postgraduate Medical Journal, 2025. Verfasst von Jiaqi Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Rituximab, Lung Diseases, Interstitial, Connective Tissue Diseases, Immunologic Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation China, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Background
Rituximab (RTX) is utilized for treating connective tissue disease-associated interstitial lung disease (CTD-ILD) by eliminating pathogenic B cells, yet its clinical benefit remains debated. This study evaluates RTX's efficacy and safety in CTD-ILD.
Methods
A literature search was conducted in PubMed, Embase, and Cochrane Library for studies on RTX in CTD-ILD up to May 24, 2024. The Joanna Briggs Institute checklist assessed study quality. Changes in forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) before and after RTX use were compared, and analyzed between RTX and control groups.
Results
1052 CTD-ILD patients from 40 studies were analyzed. RTX significantly improved FVC% (WMD = 7.10, 95% CI = 4.58-9.62, P < 0.05) and DLCO% (WMD = 5.26, 95% CI = 2.86-7.65, P < 0.01), and reduced the modified Rodnan skin score (mRSS) (WMD = −6.58, 95% CI = −8.27 to −4.89, P < 0.01) and prednisone dose (WMD = −6.94, 95% CI = −11.96 to −1.92, P < 0.01). Among RTX-treated patients, 30.3% improved, 45.3% remained stable, and 10.0% progressed. Adverse effects included infection (22.4%), hospitalization (6.7%), and mortality (5.0%).
Conclusions
RTX significantly enhances lung function in CTD-ILD patients, as shown in this systematic review and meta-analysis.
Systematic review registration
PROSPERO, identifier CRD42024520084.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1, Xian Nong Tan Street, Xicheng Dist…
- Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Dongcheng District, Beijing 100730, China.
- Diabetes Research Center of Chinese Academy of Medical Sciences, No. 1, Xian Nong Tan Street, Xicheng District, Beijing 100050, China.
- Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Dongcheng District, Beijing 100730, C…
ORCID-Profile: Hui Huang
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation China
- Chinese Academy of Medical Sciences
- Central Public-Interest Scientific Institution Basal Research Fund
- Beijing Outstanding Young Scientist Program
- National Key Research and Development Program of China
- Special Research Fund for Central Universities, Peking Union Medical College
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhang, J., Wan, Y., Liu, L., Tang, Y., Li, P., & Huang, H. (2025). Rituximab therapy for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf034
Vancouver
Zhang J, Wan Y, Liu L, Tang Y, Li P, Huang H. Rituximab therapy for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Postgraduate Medical Journal. 2025. doi:10.1093/postmj/qgaf034
BibTeX
@article{Zhang2025,
author = {Zhang, Jiaqi and Wan, Yanjun and Liu, Liheng and Tang, Yan and Li, Pingping and Huang, Hui},
title = {Rituximab therapy for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis},
journal = {Postgraduate Medical Journal},
year = {2025},
doi = {10.1093/postmj/qgaf034}
}
EUVIMED